Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy - PubMed

Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy

Marcus Pickhardt et al. Neurobiol Aging. 2017 Sep.

Abstract

The aggregation of Tau protein is a hallmark of neurodegenerative diseases including Alzheimer's disease. Previously, we generated a cell model of tauopathy based on the 4-repeat domain with the FTDP-17 mutation ΔK280 (Tau^4RDΔK) which is expressed in a regulatable fashion (tet-on). The deletion variant ΔK280 is highly amyloidogenic and forms fibrous aggregates in neuroblastoma N2a cells staining with the reporter dye Thioflavin S. The aggregation of Tau^4RDΔK is toxic, contrary to wildtype or anti-aggregant variants of the protein. Using a novel approach for monitoring in situ Tau aggregation and toxicity by combination of microscopic analysis with FACS and biochemical analysis of cells enabled the dissection of the aggregating species which cause a time-dependent increase of toxicity. The dominant initiating step is the dimerization of Tau^4RDΔK which leads to further aggregation and induces a strong increase in reactive oxygen species (ROS) and cytoplasmic Ca²⁺ which damage the membranes and cause cell death. Tau-based treatments using Tau aggregation inhibitors reduce both soluble oligomeric and fully aggregated Tau species and decrease their toxicity.

Keywords: Aggregation; Alzheimer; Cell death; Inhibitor; Tau.

Similar articles

• Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs.

  Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Khlistunova I, et al. J Biol Chem. 2006 Jan 13;281(2):1205-14. doi: 10.1074/jbc.M507753200. Epub 2005 Oct 24. J Biol Chem. 2006. PMID: 16246844

• Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.

  Fatouros C, Pir GJ, Biernat J, Koushika SP, Mandelkow E, Mandelkow EM, Schmidt E, Baumeister R. Fatouros C, et al. Hum Mol Genet. 2012 Aug 15;21(16):3587-603. doi: 10.1093/hmg/dds190. Epub 2012 May 18. Hum Mol Genet. 2012. PMID: 22611162

• Inhibition of tau aggregation in cell models of tauopathy.

  Khlistunova I, Pickhardt M, Biernat J, Wang Y, Mandelkow EM, Mandelkow E. Khlistunova I, et al. Curr Alzheimer Res. 2007 Dec;4(5):544-6. doi: 10.2174/156720507783018307. Curr Alzheimer Res. 2007. PMID: 18220518 Review.

• Analysis of in vivo turnover of tau in a mouse model of tauopathy.

  Yamada K, Patel TK, Hochgräfe K, Mahan TE, Jiang H, Stewart FR, Mandelkow EM, Holtzman DM. Yamada K, et al. Mol Neurodegener. 2015 Oct 26;10:55. doi: 10.1186/s13024-015-0052-5. Mol Neurodegener. 2015. PMID: 26502977 Free PMC article.

• Crosstalk between Oxidative Stress and Tauopathy.

  Haque MM, Murale DP, Kim YK, Lee JS. Haque MM, et al. Int J Mol Sci. 2019 Apr 22;20(8):1959. doi: 10.3390/ijms20081959. Int J Mol Sci. 2019. PMID: 31013607 Free PMC article. Review.

Cited by

• Towards a Mechanistic Model of Tau-Mediated Pathology in Tauopathies: What Can We Learn from Cell-Based In Vitro Assays?

  Sala-Jarque J, Zimkowska K, Ávila J, Ferrer I, Del Río JA. Sala-Jarque J, et al. Int J Mol Sci. 2022 Sep 29;23(19):11527. doi: 10.3390/ijms231911527. Int J Mol Sci. 2022. PMID: 36232835 Free PMC article. Review.

• The role of wild-type tau in Alzheimer's disease and related tauopathies.

  Lo CH, Sachs JN. Lo CH, et al. J Life Sci (Westlake Village). 2020 Dec;2(4):1-17. doi: 10.36069/jols/20201201. J Life Sci (Westlake Village). 2020. PMID: 33665646 Free PMC article.

• Suppressing Tau Aggregation and Toxicity by an Anti-Aggregant Tau Fragment.

  Pir GJ, Choudhary B, Kaniyappan S, Chandupatla RR, Mandelkow E, Mandelkow EM, Wang Y. Pir GJ, et al. Mol Neurobiol. 2019 May;56(5):3751-3767. doi: 10.1007/s12035-018-1326-z. Epub 2018 Sep 8. Mol Neurobiol. 2019. PMID: 30196394 Free PMC article.

• Amyloid-β-Derived Peptidomimetics Inhibits Tau Aggregation.

  Gorantla NV, Sunny LP, Rajasekhar K, Nagaraju PG, Cg PP, Govindaraju T, Chinnathambi S. Gorantla NV, et al. ACS Omega. 2021 Apr 22;6(17):11131-11138. doi: 10.1021/acsomega.9b03497. eCollection 2021 May 4. ACS Omega. 2021. PMID: 34056268 Free PMC article.

• A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro.

  Aillaud I, Kaniyappan S, Chandupatla RR, Ramirez LM, Alkhashrom S, Eichler J, Horn AHC, Zweckstetter M, Mandelkow E, Sticht H, Funke SA. Aillaud I, et al. Alzheimers Res Ther. 2022 Jan 21;14(1):15. doi: 10.1186/s13195-022-00959-z. Alzheimers Res Ther. 2022. PMID: 35063014 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Miscellaneous

  • NCI CPTAC Assay Portal